{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:41:16Z","timestamp":1794562876367,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.10.106","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:15Z","timestamp":1792756515000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study"],"prefix":"10.1016","author":[{"given":"J.","family":"Bedke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Arkosy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Mahammedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Juan-Fita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Antonyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Didas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Verzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Atduev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-H.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Zukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zurawksi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Olah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Homet","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Hoimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.10.106_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.106_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/MOU.0000000000001230","article-title":"The role of radical cystectomy and lymphadenectomy in the management of bladder cancer with clinically positive lymph node involvement","volume":"35","author":"Pfail","year":"2025","journal-title":"Curr Opin Urol"},{"issue":"9","key":"10.1016\/j.annonc.2026.10.106_bib3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.106_bib4","unstructured":"van der Heijden AG, Bruins HM, Carrion A, et al. EAU guidelines on muscle-invasive andmetastatic bladder cancer. In. Arnhem, The Netherlands: European Association of Urology Guidelines Office 2026."},{"issue":"16","key":"10.1016\/j.annonc.2026.10.106_bib5","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1200\/JCO.2015.65.9797","article-title":"Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement","volume":"34","author":"Milowsky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.10.106_bib6","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.10.106_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.annonc.2026.10.106_bib8","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: results from the TOMBOLA trial","volume":"37","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.10.106_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-58269-5","article-title":"Clinical and pathological predictors of early recurrence after neoadjuvant cisplatin gemcitabine in muscle invasive bladder cancer in the RealBLADDER study","author":"Roviello","year":"2026","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2026.10.106_bib10","article-title":"Disease management of clinical complete responders to neoadjuvant chemotherapy of muscle-invasive bladder cancer: A review of literature","volume":"12","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2026.10.106_bib11","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.annonc.2026.10.106_bib12","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.106_bib13","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.10.106_bib14","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.annonc.2020.09.011","article-title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study(\u2606)","volume":"31","author":"Bandini","year":"2020","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2026.10.106_bib15","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1158\/0008-5472.CAN-11-0950","article-title":"Human tumor cells killed by anthracyclines induce a tumor-specific immune response","volume":"71","author":"Fucikova","year":"2011","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.106_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.immuni.2013.03.003","article-title":"Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells","volume":"38","author":"Ma","year":"2013","journal-title":"Immunity"},{"issue":"19","key":"10.1016\/j.annonc.2026.10.106_bib17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.106_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa2601486","article-title":"Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer","volume":"395","author":"Galsky","year":"2026","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.10.106_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2026.10.106_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1016\/j.annonc.2026.10.106_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.urology.2012.01.090","article-title":"Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index","volume":"80","author":"Anderson","year":"2012","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.annonc.2026.10.106_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2026.10.106_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19466315.2013.807748","article-title":"Multiple testing in group sequential trials using graphical approaches","volume":"5","author":"Maurer","year":"2013","journal-title":"Statistics in Biopharmaceutical Research"},{"issue":"7","key":"10.1016\/j.annonc.2026.10.106_bib24","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.10.106_bib25","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.annonc.2026.10.106_bib26","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.10.106_bib27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2026.10.106_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2026.10.106_bib29","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annonc.2026.10.106_bib30","unstructured":"AstraZeneca Inc. Perioperative Imfinzi plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA. Published May 14, 2026. Accessed August 11, 2026. www.astrazeneca.com\/media-centre\/press-releases\/2026\/imfinzi-ev-improves-efs-os-in-bladder-cancer.html"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426068882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:55:23Z","timestamp":1792756523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426068882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0923753426068882"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.106","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.10.106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}